Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (71-80 of 436) with videos related to

Pageof 44
Sort By:
Health Services Research|September 13, 2003
Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plansMichael A Fischer, Jerry Avorn
JAMA|April 12, 2017
FDA Approval of Eteplirsen for Muscular Dystrophy-ReplyAaron S Kesselheim, Jerry Avorn
Circulation|January 24, 2008
Using computer-based decision support to close the "know do" gap in lipid-lowering therapyJerry Avorn, Niteesh K Choudhry
JAMA|April 22, 2004
Economic implications of evidence-based prescribing for hypertension: can better care cost less?Michael A Fischer, Jerry Avorn
Pharmacoepidemiology and Drug Safety|July 17, 2004
Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefitMichael A Fischer, Jerry Avorn
JAMA|February 17, 2005
University-based science and biotechnology products: defining the boundaries of intellectual propertyAaron S Kesselheim, Jerry Avorn
Archives of Internal Medicine|January 26, 2005
Coxibs, science, and the public trustDaniel H Solomon, Jerry Avorn
Annals of Internal Medicine|February 26, 2009
Communicating drug benefits and risks effectively: there must be a better wayJerry Avorn, William H Shrank
JAMA|January 18, 2007
The role of litigation in defining drug risksAaron S Kesselheim, Jerry Avorn
JAMA|January 6, 2017
New "21st Century Cures" Legislation: Speed and Ease vs ScienceAaron S Kesselheim, Jerry Avorn
Pageof 44

Showing results (71-80 of 436) with videos related to

Sort By:
Pageof 44
Health Services Research|September 13, 2003
Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plansMichael A Fischer, Jerry Avorn
JAMA|April 12, 2017
FDA Approval of Eteplirsen for Muscular Dystrophy-ReplyAaron S Kesselheim, Jerry Avorn
Circulation|January 24, 2008
Using computer-based decision support to close the "know do" gap in lipid-lowering therapyJerry Avorn, Niteesh K Choudhry
JAMA|April 22, 2004
Economic implications of evidence-based prescribing for hypertension: can better care cost less?Michael A Fischer, Jerry Avorn
Pharmacoepidemiology and Drug Safety|July 17, 2004
Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefitMichael A Fischer, Jerry Avorn
JAMA|February 17, 2005
University-based science and biotechnology products: defining the boundaries of intellectual propertyAaron S Kesselheim, Jerry Avorn
Archives of Internal Medicine|January 26, 2005
Coxibs, science, and the public trustDaniel H Solomon, Jerry Avorn
Annals of Internal Medicine|February 26, 2009
Communicating drug benefits and risks effectively: there must be a better wayJerry Avorn, William H Shrank
JAMA|January 18, 2007
The role of litigation in defining drug risksAaron S Kesselheim, Jerry Avorn
JAMA|January 6, 2017
New "21st Century Cures" Legislation: Speed and Ease vs ScienceAaron S Kesselheim, Jerry Avorn
Pageof 44